Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
Sponsor: University Hospital, Lille
Summary
Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2026-01-01
Completion Date
2027-01-26
Last Updated
2026-01-02
Healthy Volunteers
No
Conditions
Interventions
Measurement of resistance through forced oscillations and continuous measurement of ventilation and inspiratory capacity during TM6
Measurement of resistance through forced oscillations and continuous measurement of ventilation and inspiratory capacity during TM6
Locations (1)
University Hospital
Lille, France